Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Andrew Berens

Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug

Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat.

Investors Business Daily

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'

Blueprint Medicines is Tuesday's IBD Stock Of The Day. Shares are breaking a trendline, giving investors an early entry within a flat base.

Investors Business Daily

Is This Dividend Stock a Buy Now?

With a robust portfolio, this top pharma stock is a good mix of growth and income.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Investors Business Daily

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

Investors Business Daily

AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth

AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.

Investors Business Daily

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days

Mirati Therapeutics' pain continued Thursday amid a series of analyst downgrades after MRTX stock lost about half of its value in three days.

Investors Business Daily

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up

Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.

Investors Business Daily

Aveo Stock Continues Its Bullish Run After Snagging $566 Million LG Chem Buyout

Aveo Oncology agreed to be acquired by Korea's LG Chem on Tuesday, and Aveo stock skyrocketed to a near two-year high on the news.

Investors Business Daily

Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint

Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed.

Investors Business Daily

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech?

Merck is now in advanced talks to buy Seagen for roughly $40 billion, according to reports that sent SGEN stock higher Thursday.

Investors Business Daily

IBD Stock Of The Day: Bristol Myers Eyes Breakout After $4.1 Billion Buyout

Bristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting investors with an early entry.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug

Investors Business Daily

The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed

Shares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising — test results for a lung cancer treatment.

Investors Business Daily

Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash

Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.

Investors Business Daily

Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim

Seagen CEO Clay Siegall was placed on leave after a domestic abuse allegation, the biotech company said Monday as SGEN stock dropped.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.